In response to one of your final comments. I have

In response to one of your final comments. I have said on many occasions that having a sales partner for CLIA is less important than having a sales JV partner for FDA approval. ICON has the relationships to target the clinical trial market under CLIA and be very successful. We will see revenue rise quickly next year Q1-Q4. I am quite sure that the 50 meetings they had at BIO recently were talking to the major players with Alzheimer's clinical trials. Technically, they were pre-sales calls raising awareness and generating interest. The JV partner is more important for commercialization. I think that will happen very soon with a large upfront payment. FDA approval might be 12+ months off after CLIA approval but there is a lot of planning and other potential markets to target before the US.

If we get good data and sign a JV partner like a large Diagnostic company, we won't have to worry about price per share or large reverse splits. The fact AMBS signed. Work Order with ICON for $150,000 and ICON agreed to take on the work tells me the data will be more than good. ICON would not sign on to run a bad test very few times. They know it will be good and they will make a ton of money.